Literature DB >> 25090759

[Epidemiology and risk factors for cancer of the uterus].

Claire Bonneau, Morgane Perrin, Martin Koskas, Anne-Sophie Genin, Roman Rouzier.   

Abstract

Cancers of the uterus correspond to cervical cancers and uterine corpus cancers. Cervical cancer is common among young women, especially in immunocompromised populations. Its carcinogenesis is induced by the human papilloma virus (HPV). All factors promoting the HPV contamination and/or limiting the clearance of HPV or promoting its progression are risk factors for cervical cancer: sex at an early age, multiple sexual partners, multiparty, smoking, hormonal contraceptives, immunosuppression or certain infections. Cancers of the uterine corpus, substantially represented by endometrial cancers, represent the fourth leading cause of cancer in women in France. Risk factors are related to hyperestrogenism with early age of menarche and late menopause, obesity, diabetes, inadequate hormone-replacement therapy for menopause. Endometrial cancers fall in the scope of familial cancers making evoke a Lynch syndrome/HNPCC.

Entities:  

Mesh:

Year:  2014        PMID: 25090759

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  3 in total

1.  ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins.

Authors:  Lixia Bai; Rui Mao; Jintao Wang; Ling Ding; Shiwen Jiang; Chenfei Gao; Huijie Kang; Xiao Chen; Xuesong Sun; Juan Xu
Journal:  Med Oncol       Date:  2015-02-03       Impact factor: 3.064

Review 2.  Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.

Authors:  Alice Trefoux Bourdet; Dominique Luton; Martin Koskas
Journal:  Int J Womens Health       Date:  2015-03-26

3.  Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway.

Authors:  Mengting Li; Yulin He; Cheng Peng; Xiaofang Xie; Guanying Hu
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.